Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Overcoming proteasome inhibitor resistance in the immunotherapy era

Trends in Pharmacological Sciences(2023)10.1016/j.tips.2023.05.006Source: DataRank Database

Overcoming proteasome inhibitor resistance in the immunotherapy era is a research paper published in Trends in Pharmacological Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 4.44)OA: hybridTopics (24)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Alexis Talbot ORCID,Arun P. Wiita ORCID,Bonell Patiño-Escobar ORCID

Live enrichment

PubMed:37344251 OpenAlex:https://openalex.org/W4381166951

National Cancer Institute

Grant: R01 CA226851

Multiple Myeloma Research Foundation

National Institutes of Health

FWCI

4.44

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttp://www.cell.com/article/S0165614723001116/pdf

publisherhttp://www.cell.com/article/S0165614723001116/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0165614723001116?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0165614723001116?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.tips.2023.05.006

Fields of Study

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathwaysProtein Degradation and Inhibitors

MeSH Terms

HumansImmunotherapyMitochondriaMultiple MyelomaDrug Resistance, NeoplasmProteasome Inhibitors

Keywords

ProteasomeImmunotherapyMultiple myelomaMedicineDiseaseCancerCancer researchBioinformaticsImmunologyBiologyInternal medicineCell biologyResistanceProteasome inhibitormyeloma

Sustainable Development Goals

SDG 0: Good health and well-being